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Background: Pancreatic cancer is one of the most aggressive human malignancies with a extremely low 5-year
survival rate. Hence, the search for more effective anti-pancreatic cancer agents is urgent.
Methods: PaTu8988 pancreatic cancer cells were treated with different concentrations of suberoylanilide
hydroxamic acid (SAHA), cell survival, proliferation, migration and vasculogenic mimicry (VM) were analyzed.
Associated signaling changes were also analyzed by RT-PCR and Western blots.
Results: Here, we reported that SAHA, a histone deacetylase inhibitor (HDACi), exerted significant inhibitory
efficiency against pancreatic cancer cell survival, proliferation, migration and VM. SAHA dose-dependently inhibited
PaTu8988 pancreatic cancer cell growth with the IC-50 of 3.4 ± 0. 7 μM. Meanwhile, SAHA suppressed PaTu8988 cell
cycle progression through inducing G2/M arrest, which was associated with cyclin-dependent kinase 1 (CDK-1)/
cyclin-B1 degradation and p21/p27 upregulation. Further, SAHA induced both apoptotic and non-apoptotic death
of PaTu8988 cells. Significantly, SAHA suppressed PaTu8988 cell in vitro migration and cell-dominant tube formation
or VM, which was accompanied by semaphorin-4D (Sema-4D) and integrin-β5 down-regulation. Our evidences
showed that Akt activation might be important for Sema-4D expression in PaTu8988 cells, and SAHA-induced
Sema-4D down-regulation might be associated with Akt inhibition.
Conclusions: This study is among the first to report the VM formation in cultured human pancreatic cancer cells.
And we provided strong evidence to suggest that SAHA executes significant anti-VM efficiency in the progressive
pancreatic cancer cells. Thus, SAHA could be further investigated as a promising anti-pancreatic cancer agent.
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Pancreatic cancer is one of the most aggressive human
malignancies, with less than 5% of patients still alive five
years after diagnosis [1]. In 2012, it is estimated that a
total of 43,920 patients will be diagnosed with pancreatic
cancer in the United States, and 37,390 will die of this
disease [2]. Pancreatic cancer is characterized by a rapid
disease progression and highly invasive phenotype. Most
patients are with unresectable tumor at the time of diag-
nosis, leaving chemotherapy and radiation as the only
available treatment options [3]. For the past decades,
gemcitabine has been the standard treatment for advanced
pancreatic cancers, prolonging survival by 5–6 months
[4]. However, a large percentage of pancreatic cancers do
not respond to gemcitabine, probably due to the high level
of intrinsic and acquired chemo-resistances [5].
Angiogenesis is essential for tumor growth and metas-
tasis. Tumor-associated angiogenesis is critical for pan-
creatic cancer progression [6]. Several modes of vessel
formation have been proposed so far: vasculogenesis,
angiogenesis, intussusceptions, vascular cooption and vas-
culogenic mimicry (VM) [7]. VM is the process where
fluid-conducting channels were formed by the highly inva-
sive and genetically dysregulated tumor cells [8]. Tumors
with high VM abilities are often highly aggressive and
associated with poor prognosis [8-10]. VM has been
observed in a variety of aggressive tumors including
carcinomas, breast cancers, liver cancers, ovarian can-
cers, prostate cancers, sarcomas, gliomas and melano-
mas [11,12]. Pancreatic cancer represents one of the
most vascularized and angiogenic solid tumors [13]. In
the current study, we found that many human pancre-
atic cancer cells could also form tube like structure
(VM) in vitro.
In the current study, we aimed to seek novel and more
efficient treatment strategies by targeting angiogenic mim-
icry in pancreatic cancer cells. Suberoylanilide hydroxamic
acid (SAHA) belongs to the histone deacetylases (HDAC)
inhibitors (HDACi), which represent a new class of anti-
cancer therapeutics. Studies have confirmed its high effi-
ciency in inhibiting angiogenesis in pre-clinical animal
models and early phase clinical trials [14,15]. SAHA in-
hibits the in vitro and in vivo growth of transformed hu-
man cancer cells, including prostate, bladder and ovarian
tumor cells [15,16]. SAHA has been tested in phase I and
phase II clinical trials for the treatment of various malig-
nancies, and has demonstrated significant anti-cancer effi-
ciency at well-tolerated doses [15,16]. Meanwhile, studies
have shown that SAHA exhibits profound inhibitory
effects against human pancreatic cancer cells [17]. How-
ever, the potential effect of SAHA on VM and proli-
feration of highly metastasis pancreatic cancer cells is
not fully studied. Further, the underlying mechanisms
remain inconclusive. In this study, we found thatSAHA inhibits in vitro proliferation, migration and
VM in a highly aggressive human pancreatic cancer
cells (PaTu8988).Methods
Chemical and reagents
SAHA (Purity ≥99%) was purchased from Selleck Chemi-
cals (Houston, TX). Matrigel and the anti-Semaphorin-4D
(Sema-4D) antibody were obtained from BD Biosciences
(San Jose, CA). Trypan blue was purchased from Beyotime
Biotechnology (Shanghai, China). Annexin V-FITC apop-
tosis detection kit was purchased from Biotech Co., Ltd
(Nanjing, China). RNase-free DNase I was from Qiagen
(Hilder, Germany). RevertAid™ First Strand cDNA Synthe-
sis Kit was purchased from Fermentas Life Sciences (Chi-
cago, IL). Taq™ DNA Polymerase was from TaKaRa
Biotechnology Co., Ltd (Dalian, China). Propidium iodide
(PI), monoclonal antibody against β-actin and gelatin were
obtained from Sigma (St. Louis, Mo). The anti-cyclin-
D1 antibody was obtained from ABGENT (Suzhou,
China). Anti-epidermal growth factor receptor (EGFR)
and platelet-derived growth factor receptor (PDGFR) anti-
bodies were purchased from Santa Cruz Biotech (Santa
Cruz, CA). Akt, p-Akt (Ser 473), p70S6 kinase (S6K1),
p-S6K1 (Thr 389), S6, p-S6 (Ser 235/236), mTOR, p-
mTOR (Thr 289), Ulk1, p-Gsk-3β, Ulk1, Erk1/2 and
p-Erk1/2 antibodies were purchased from Cell Signal-
ing Tech (Beverly, MA). Primers were synthesized by
GENEWIZ, Inc. (Suzhou, China).Cell culture
As previously described [18], human pancreatic cancer
cell lines PaTu8988, Bxpc-3, Aspc-1, CFPAC-1, PaTu8988,
SW1990, Panc-1 as well as normal hypertrophic scar fi-
broblasts (HSF) were obtained from Chinese Academy of
Sciences Cell Bank (Shanghai, China). Cells were cultured
in RPMI (HyClone, Shanghai, China) with 10% heat-
inactivated fetal bovine serum (FBS), with 100 U/ml of
penicillin G and 100 μg/ml of streptomycin in a 5% CO2
incubator at 37°C. Fresh peripheral blood mononuclear
cells (PBMNCs) from three healthy adults were collected
and separated by Ficoll-Hipaque density sedimentation as
previously reported [18], the cells were then cultured
in RPMI 1640 medium supplemented with 10% heat-
inactivated FBS, 100 U/ml penicillin G and 100 μg/mL
streptomycin. The study was approved by the institutional
review board of the Third Hospital affiliated to Soochow
University and all other authors’ institutions, and written
informed consent was obtained from all three human par-
ticipants. All clinical investigations were conducted ac-
cording to the principles expressed in the Declaration of
Helsinki.
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Pancreatic cancer PaTu8988 cell growth was assessed
using the trypan blue exclusion test. Cells were seeded
in 6-well plates for 24 h, various concentration of SAHA
was added, cells were further cultured for additional
48 h. Afterwards, cells were harvested and stained with
trypan blue. The unstained (“survival”) cells were coun-
ted in a Neubauer chamber, and the number was ex-
pressed as the percentage change of control group. The
IC-50, defined as the drug concentration at which cell
growth was inhibited by 50%, was assessed by SPSS 16.0
software. All experiments were repeated at least three
times.Colony formation assay
PaTu8988 cells treated with SAHA for 48 h were har-
vest, a total of 1 × 103 cells per well suspended in 150 μL
of Mix agar with 1.5 mL DMEM/10% FBS were plated
in 30 mm plates overlying a 1% agar-DMEM/10% FBS
(1:1) bottom layer. After 3 weeks, colonies were photo-
graphed at 4×. The remaining survival large colonies
(>100 μM in diameter) were manually counted.Cell cycle assay
PaTu8988 cells were grown in T75 flasks and treated
with indicated dosage of SAHA for 48 h. After the treat-
ment, the cells were fixed with 70% ethanol overnight at
4°C, washed with PBS, re-suspended in 500 μL PBS with
100 μg/mL RNase and incubated for 30 min at 37°C.
After that, 2.5 μL of PI solution (10 mg/mL) was added.
The DNA contents of PI-stained cells were analyzed
using a flow cytometry (Becton Dickinson FACS
Calibur).Cell apoptosis assay
PaTu8988 cell apoptosis was detected by the Annexin V
Apoptosis Detection Kit (Beyotime, Shanghai, China)
according to the manufacturer’s protocol. Briefly, one
million cells with indicated treatments were stained
with FITC-Annexin V and PI (Beyotime, Shanghai, China).
Both early (annexin V+/PI−) and late (annexin V+/PI+)
apoptotic cells were sorted by fluorescence-activated cell
sorting (FACS) (Becton Dickinson FACS Calibur).Cell morphologic analysis
A total of 4 × 104 PaTu8988 cells were seeded on
glass cover slips in the six well plate and treated with
the indicated concentration of SAHA for 48 h. Cells
were fixed and stained with Wright-Giemsa stain. The
slides were photographed using oil microscopy (×1000
magnification).In vitro tube formation assay or vasculogenic mimicry
(VM) assay
The tumor cell formation of capillary structure in vitro
was tested as we previously described [19,20].
Cellular immuno-fluorescence staining
PaTu8988 cells were seeded on glass cover slips in six
well plates and treated with described dosage of SAHA
for 48 h. Cells on the cover slip were then fixed with 4%
paraformaldehyde for 10 min at room temperature with-
out permeabilization. Slides were washed three times with
phosphate buffered saline (PBS), blocked with 5% bovine
serum albumin (BSA) for 1 h at 37°C, followed by incu-
bation with the primary antibody overnight at 4°C, and
the secondary antibody for 1 h at room temperature.
The slides were photographed using OLYMPUS FSX-
100 microscope.
MTT cell viability assay
The cell viability was measured by the 3-[4,5-
dimethylthylthiazol-2-yl]-2,5 diphenyltetrazolium brom-
ide (MTT) method, as described before [21]. Briefly, the
PaTu8988 cells were collected and seeded in 96-well
plate at a density of 2 × 105 cells/cm2. Different seeding
densities were optimized at the beginning of the expe-
riments. After treatment, 20 μl of MTT tetrazolium
(Sigma, St. Louis, MO) salt dissolved in PBS at a concen-
tration of 5 mg/mL was added to each well and incubated
in a CO2 incubator for additional 2 hrs. Finally, the me-
dium was aspirated very carefully and 150 μl/well of
DMSO (Sigma, St. Louis, MO) was added to dissolve for-
mazan crystals. The absorbance of each well was obtained
using a plate reader at a test wavelength of 490 nm with a
reference wavelength of 630 nm. The value of treatment
group was always normalized to that of control group.
“Scratch” assay
As described [22], twelve-well plates were pre-coated
with poly-lysine (30 μg/ml), followed by further BSA
blocking. A sufficient number of PaTu8988 cells were
plated, so that they became confluent in the wells right
after attachment (~1–2 h). Same area of each well is then
displaced by scratching a same straight line through the
layer with a needle. Floating cells were washed away by
warm PBS. Cells were further incubated with the indi-
cated concentration of SAHA for 24 h, and stained with
Wright-Giemsa to see migration “gap”. Mitomycin C
(10 μg/ml) was always included in the culture media to
prevent cell proliferation.
PCR analysis
Total RNA was extracted from PaTu8988 cells and trea-
ted with RNase-free DNase I. The quality of RNA was test
by DU-800 Nucleic Acid/Protein Analyzer (Beckman,
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tion using RevertAidTM First Strand cDNA Synthesis
Kit and oligo (dT) in a 20 μL reaction containing 5 μg of
total RNA. Next, PCR was performed in each 25 μL
PCR reaction containing 0.5 μL diluted cDNA, TaKaRa
rTaq DNA Polymerase and indicated primers. The PCR
reaction contained an initial denaturation at 94°C forTable 1 Primer sequences for semi-quantitative RT-PCR
Gene name (mRNA ID) Primer name Prim
β-actin Forw AAG
(NM_001101.3) Rev CGC
Cyclin D1 Forw CAT
(NM_053056.2) Rev CGC






























Note: Forw: the forward primer; Rev: the reverse primer; CDK1: cyclin-dependent kin
receptor 1; HIF1A: hypoxia inducible factor 1, alpha subunit; MAGED1: melanoma an
endothelial growth factor A; Sema4D:Sema domain, immunoglobulin domain (Ig), t
interacting protein family, member 2; MAGEF1: melanoma antigen family F1; MAGE
RUNX1: runt-related transcription factor 1.3 min, followed each PCR cycle by de-naturation at
94°C for 30 seconds, annealing at 55–68°C for 30 sec-
onds, and extension at 72°C for 1 min for a total of
22–36 cycles, depending on the primer length and the
molecular weights of target genes. PCR products were an-
alyzed by 1.5% agarose gel. Primers used in this study were



















































ase 1; CDK4: cyclin-dependent kinase 4; FGFR1: fibroblast growth factor
tigen family D1; FGFR1:fibroblast growth factor receptor 1; VEGFA: vascular
ransmembrane domain and short cytoplasmic domain, 4D; WIPF2: WAS/WASL
D1: melanoma antigen family D1; ZFP106: zinc finger protein 106 homolog;
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As described before [21], aliquots of 30–40 μg of protein
from each sample (treated as indicated in the legends)
was separated by 10% SDS–polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred onto a polyvinyli-
dene difluoride (PVDF) membrane (Millipore, Bedford,
MA). After blocking with 10% instant nonfat dry milk
for 1 h, membranes were incubated with the specific
antibody overnight at 4°C, followed by incubation with
corresponding secondary antibody (HRP-conjugated anti-
rabbit or anti-mouse IgG at the appropriate dilutions) for
30 min to 1 h at room temperature. Antibody binding was
detected with the enhanced chemiluminescence (ECL) de-
tection system (Amersham Biosciences, Piscataway, NJ).
The intensity of interested band was quantified using Ima-
geJ software, and the value was normalized to correspond-
ing loading controls.
Statistic analysis
The data shown in this study represented the mean ± S.E.
Differences between the groups were assessed by one-way
ANOVA using SPSS 16.0 software. The significance of dif-
ferences was indicated as *P < 0.05 and **P < 0.01.
Results
SAHA inhibits the proliferation of PaTu8988 pancreatic
cancer cells
Figure 1A showed the chemical structure of SAHA.
Considering that uncontrolled proliferation and robust
angiogenesis (i.e. VM) contribute to the growth and me-
tastasis of pancreatic cancers, we first investigated the
potential role of SAHA on the pancreatic cancer cell
proliferation. As shown in Figure 1B, SAHA dose-
dependently inhibited PaTu8988 cell proliferation with
the IC-50 of 3.4 ± 0.7 μM. However, it had almost no ef-
fect on the proliferation of HSF (hypertrophic scar fi-
broblasts) (Figure 1E) and normal PBMNCs (peripheral
blood mononuclear cells) (Figure 1F) at the dose up to
40 μM. These results suggested that SAHA has selective
inhibitory efficiency against pancreatic cancer cells, but
not normal mononuclear cells or HSF cells. To further
explore the inhibitory ability of SAHA on PaTu8988 cell
proliferation under more stringent conditions, the colo-
nial survival assay was performed. The results showed
that the number of remaining survival colonies in SAHA-
treated group was significantly lower than that of control
group (Figure 1C and D). Hence, these results demonstra-
ted that SAHA effectively inhibits PaTu8988 cell in vitro
proliferation.
SAHA affects cell cycle progression of PaTu8988 cells
Next, we analyzed the cell cycle distribution in SAHA-
treated PaTu8988 cells. As shown in Figure 2A and B, a
large population of SAHA (>5-10 μM)-treated PaTu8988cells were arrested in G2/M phase. Meanwhile, RT-PCR
results showed that the mRNA expressions of cyclin-
dependent kinase 1 (CDK-1), cyclin-D1 and cyclin-B1
were down-regulated after SAHA treatment, while the
p21 and p27 mRNAs were markedly increased (Figure 2C).
The CDK-2, CDK-4 and p53 mRNAs were not affected
by SAHA (Figure 2C). Further, western blot results in
Figure 2D confirmed that the protein level of cyclin-D1 was
markedly decreased after SAHA (10 or 20 μM) treatment,
while p21 and p27 protein expressions were significantly
upregulated. Immuno-fluorescence results in Figure 2E
further confirmed p21 upregulation and nuclear trans-
location after SAHA stimulation in PaTu8988 cells. These
results suggested that SAHA suppresses cell cycle pro-
gression by inducing G2/M arrest in PaTu8988 cells; such
effect of SAHA is associated with perturbation of cell
cycle-associated proteins.SAHA induces both apoptotic and non-apoptotic death of
PaTu8988 cells
Next, we examined whether the inhibitory effect of
SAHA on PaTu8988 cell proliferation was due to cell
apoptosis. As shown in Figure 3A and B, the population
of apoptotic (Annexin V positive) PaTu8988 cells in-
creased significantly after high dose SAHA (>10 μM)
treatment. Meanwhile apoptosis-associated proteins were
also changed. Poly (ADP-ribose) polymerase (PARP) and
caspase-3 were down-regulated after SAHA treatment,
while cleaved-PARP was up-regulated (Figure 3C). We
failed to see an increase of cleaved-caspase-3 in SAHA-
treated PaTu8988 cells (Figure 3C). Interestingly, we also
noticed a small population of non-apoptotic “dead”
PaTu8988 cells (Annexin V negative and PI positive)
after SAHA treatment. Together, these results suggested
that both apoptotic and non-apoptotic cell death might
contribute to SAHA-induced anti-proliferation effect in
PaTu8988 cells.SAHA induces differentiation and inhibits migration of
PaTu8988 cells
We also examined the potential effect of SAHA on the
morphology change of PaTu8988 cells. The PaTu8988
cells were incubated with SAHA for 48 h. Afterwards,
cells were stained with Wright-Giemsa to see their mor-
phology. As shown in Figure 4A, control cells were small
and had little hyper-chromatism in cytoplasm, indicating
an undifferentiated shape. While the SAHA-treated cells
were bigger, and were with full of light cytoplasm and cy-
toplasm projections: a typical differentiated shape. These
results suggested that SAHA might induce PaTu8988 cell
differentiation. We also tested the effect of SAHA on cell
migration through in vitro “scratch” assay; results in
Figure 4B demonstrated that SAHA dose-dependently
Figure 1 SAHA inhibits the proliferation of PaTu8988 pancreatic cancer cells. Chemical structure of SAHA is shown in (A). Human pancreatic
cancer PaTu8988 cells were incubated with SAHA at indicated dosage for 48 h, and cell growth was measured by trypan blue exclusion test. The
IC-50 was calculated by SPSS 16.0 software (B). PaTu8988 cells were treated with SAHA (20 μM). The colony formation assay was performed, and
the number of colonies was manually counted (C and D). Human hypertrophic scar fibroblasts (HSF) were treated with various concentration of
SAHA for 48 h, followed by Wright-Giemsa staining and photograph by OLYMPUS FSX-100 microscope (E). Peripheral blood mononuclear cells
(PBMNCs) were treated with various concentration of SAHA for 48 h, cell death was detected by PI staining through FACS sorting (F). Experiments
in this figure were repeated three times, and similar results were obtained. The data in this figure was expressed as mean ± S.E. **P < 0.01 vs. Ctrl
(C). Magnification: 1:100 (E).
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Figure 2 SAHA affects cell cycle progression of PaTu8988 cells. PaTu8988 cells were incubated with SAHA at indicated dosage for 48 h, DNA
content of PI-stained cells was analyzed by flow cytometry (A), and cell cycle distribution was analyzed (B). The mRNAs of cell cycle regulatory
genes were detected by semi-quantitative RT-PCR assay (C). The protein expressions of cyclin-D1, p21, p27 and β-actin were also tested by
western blots (D), and the expression and sub-cellular location of p21 were also measured by immuno-fluorescence (E). Experiments in this figure
were repeated three times, and similar results were obtained. The data in this figure was expressed as mean ± S.E. *P < 0.05 vs. Ctrl, **P < 0.01 vs.
Ctrl (B). Magnification: 1:400 (E).
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ficiency against PaTu8988 cell in vitro migration. The
inhibitory effects of SAHA on cell migration were notsecondary to decreased viability, as no significant cell via-
bility decrease was observed after indicated SAHA treat-
ment for 24 h (Figure 4C).
Figure 3 SAHA induces both apoptotic and non-apoptotic death of PaTu8988 cells. PaTu8988 cells were incubated with SAHA at indicated dosage
for 48 h, FITC-annexin V and PI stained cells were sorted by flow cytometry (A). The distribution of cell apoptosis was analyzed (B). The protein
expressions of PARP, cleaved-PARP, caspase-3, cleaved-caspase-3 and β-actin were detected by western blots (C). Experiments in this figure were
repeated three times, and similar results were obtained. The data in this figure was expressed as mean ± S.E. *P < 0.05 vs. Ctrl, **P < 0.01 vs. Ctrl (B).
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Results above have shown that SAHA inhibits PaTu8988
cell in vitro migration. VM is the formation of fluid-conducting channels by highly invasive and genetically
dysregulated tumor cells [9]. Through in vitro tube for-
mation assay, we observed the VM formation in multiple
Figure 4 SAHA induces differentiation and inhibits migration of PaTu8988 cells. (A) PaTu8988 cells were seeded on glass cover slips in six-well
plate and treated with SAHA for 48 h. Cells were stained with Wright-Giemsa stain and photographed by oil microscopy for 1000×. (B) PaTu8988
cells were incubated with SAHA at indicated dosage for 24 h, the in vitro cell migration was analyzed by “scratch” assay as described, cell viability
was analyzed by MTT assay (C). Experiments in this figure were repeated three times, and similar results were obtained. Magnification: 1:200 (B).
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and CFPAC-1) (Figure 5A). To examine whether SAHA
have anti-VM ability, the PaTu8988 cells, pretreated with
or without SAHA, were seeded onto a Matrigel layer and
the capillary tube formation ability was monitored and
photographed. As shown in Figure 5B-C, the PaTu8988
cells again formed a good tube like structure, which was
inhibited by SAHA. Note that 20 μM of SAHA almost
completely disrupted VM formation. VM-associated genes
were also tested in control and SAHA-treated PaTu8988
cells. As shown in Figure 5D, Sema-4D and integrin-β5
mRNAs were significantly down-regulated by SAHA
(10 and 20 μM), and the HIF-2A mRNA expression was
also suppressed by SAHA (20 μM). Interestingly, othertumor VM and angiogenic genes including RUNX1, HIF
(Hypoxia-inducible factor)-1A, integrin-α5 and VEGF
(vascular endothelial growth factor)-A were not affec-
ted. Further, western blot results (Figure 5E) confirmed
that Sema-4D protein was down-regulated by SAHA in
PaTu8988 cells. Hence, these results suggested that SAHA
inhibited PaTu8988 cell in-vitro VM, which was associated
with Sema-4D and integrin-β5 down-regulation.
Akt is important for Sema-4D expression in PaTu8988
cells, inhibited by SAHA
Since previous studies have confirmed that Akt and its
downstream mTORC1 is important for both survival and
migration of pancreatic cancer cells [23-29], we thus
Figure 5 SAHA suppresses PaTu8988 cell vasculogenic mimicry (VM). The six human pancreatic cancer cells including Bxpc-3, Aspc-1, CFPAC-1,
PaTu8988, SW1990 and Panc-1 were harvested and suspended in RPMI-1640 plus 10% FBS at a density of 2 × 105/mL. A volume of 150 μL/well of
Matrigel matrix was transferred to a 48-well plate at 37°C for 30 min. Then the cells were transferred to each well. The cells were further incubated
at 37°C, 5% CO2 for 4–6 h, the formed tubes were stained with Wright-Giemsa and photographed by OLYMPUS FSX-100 microscope (A).
PaTu8988 cells were treated with the indicated concentration of SAHA for 24 h, and subjected to a tube formation assay as described (B). The
capillary-like structures were imaged and analyzed for quantification (C). The mRNAs of vasculogenic and angiogenic genes were determined by
semi-quantitative RT-PCR assay (D), and the expression of Sema-4D was detected by western-blot (E). Experiments in this figure were repeated three
times, and similar results were obtained. The data in this figure was expressed as mean ± S.E. **P < 0.01 vs. Ctrl (C). Magnification: 1:200 (A and B).
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Akt-mTORC1 in PaTu8988 pancreatic cancer cells. Also,
it has been suggested that Akt signaling is linked with can-
cer cell VM [30,31], we tested whether this signaling path-
way was important for Sema-4D expression. As shown in
Figure 6A and B, SAHA (10–40 μM) significantly inhib-
ited activation of Akt. Meanwhile, mTORC1 activation,
indicated by p-mTOR, p-S6K1 and p-S6, was also sup-
pressed by SAHA (Figure 6A and B). Expression of Ulk1,
an indicator of autophagy activation, was not affected by
SAHA treatment (Figure 6A). We proposed that growth
factor receptors’ degradation might be responsible for
Akt-mTORC1 inhibition by SAHA, since SAHA admi-
nistration down-regulated epidermal growth factor recep-
tor (EGFR) and platelet-derived growth factor receptor β
(PDGFRβ) expression (Figure 6C). Interestingly, as shown
in Figure 6D, the Akt inhibitor perifosine, but not the
mTORC1 inhibitor rapamycin, inhibited Sema-4D ex-
pression in PaTu8988 cells, indicating that Akt rather
than mTORC1 is important for Sema-4D expression. Even
more intriguingly, although perifosine blocked Akt activa-
tion, it only inhibited, but not blocked S6 phosphorylation.
These results suggested that other upstream signals beside
Akt might also be responsible for mTORC1 or S6 activa-
tion in this particular cell line, and that SAHA’s inhibitoryability on mTORC1 activation might not solely depend on
Akt inhibition.Discussion
Gemcitabine is the only standard chemotherapy for pan-
creatic cancer patients. However, the median survival with
gemcitabine treatment was still a dismal 5.65 months with
1-year survival rate of 18% [32]. In the current study, we
used PaTu8988 pancreatic cancer cells as a cell model
to investigate anti-cancer activity of SAHA. Our results
demonstrated that SAHA exerted profound inhibitory effi-
ciency against PaTu8988 cells. SAHA dramatically inhib-
ited PaTu8988 cell survival, proliferation, migration, and
more importantly tuber formation or VM. This study
is among the first to report the VM formation in hu-
man pancreatic cancer cells. Further, we provided strong
evidence to suggest that SAHA executed a significant
anti-VM effect in human pancreatic cancer cells. Mean-
while, SAHA also promoted cancer cell cycle arrest and
cell death (both apoptotic and non-apoptotic). Thus,
SAHA could be further investigated as a promising anti-
pancreatic cancer agent.
SAHA induces PaTu8988 cell cycle arrest at G2/M
phase probably via down-regulating cyclin B1. Previous
Figure 6 Akt is important for Sema-4D expression in PaTu8988 cells, inhibited by SAHA. PaTu8988 cells were stimulated with indicated
concentration of SAHA, cells were further cultured for indicated time, expressions of p-Akt (Ser 473), Akt, p-mTOR (Ser 2448), mTOR, p-S6K1
(Thr 389), S6K1, p-S6 (Ser 235/236), S6, SHP-2, EGFR, PDGFRβ and β-actin were detected by western blots (A-C). PaTu8988 cells were treated with
Akt inhibitor perifosine (10 μM), mTORC1 inhibitor rapamycin (100 nM) or Erk/MAPK inhibitor PD98059 (10 μM), cells were further cultured for
24 h, expressions of p-Akt (Ser 473), Akt, p-S6 (Ser 235/236), S6, p-Gsk3β, β-actin, Erk1/2, p-Erk1/2 and Sema-4D were tested by western blots.
Akt/mTOR/S6K1 phosphorylation in (A), Akt/S6 phosphorylation in (B), EGFR/PDGFRβ expression in (C), and Sema-4D expression in (D) were
quantified after normalization to corresponding loading controls, and the number was presented as fold change vs. untreated (“C”) control
group. Experiments in this figure were repeated three times, and similar results were obtained.
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involved in G2/M arrest [33]. And constitutive activation
of cyclin B1 overrides p53-mediated G2/M arrest [32].
In our study, we found that SAHA induced expressions
of CDK inhibitors p21 and p27, which are known to
affect G2/M cycle progression [34]. Here we observed a
significant cell apoptosis after high dose of SAHA treat-
ment, the mechanism of SAHA-induced apoptosis may
be associated with PARP and caspase-3 degradation, as
suggested by other studies [34,35]. Intriguingly, SAHA
also induced non-apoptotic cell death in PaTu8988 cells.
This result is not surprising, as recent studies have ob-
served non-apoptotic death, in particular autophagic cell
death induced by SAHA [36,37].
Tumor vasculogenic mimicry (VM), which is charac-
terized by the tumor cell-lined vessels, was first found
from metastatic melanoma by Hendrix MJ group in 1999
[34]. Hence, VM has been targeted for anti-cancer ther-
apy. Here we first reported that multiple pancreatic cancer
cell lines formed a good tube like structure in Matrigel
in vitro. Significantly, SAHA greatly inhibited PaTu8988
cell-mediated VM in vitro, such an effect was associated
with down-regulating Sema-4D and integrin-β5, two key
VM associated proteins.
Here we observed a significant down-regulation of
Sema-4D by SAHA in PaTu8988 cells. Sema-4D expres-
sion is seen in a wide range of human tumors including
prostate, colon, breast, oral, head and neck carcinomas
[37]. Sema-4D is a cell surface membrane protein that is
shed from tumor cells and promotes endothelial cell
proliferation, migration, angiogenesis, and tumor invasivegrowth through its action on its cognate endothelial re-
ceptor, plexin B1 [35]. In the absence of Sema-4D, tumor
growth and tumor angiogenesis in vivo are greatly im-
paired [36]. Researchers have demonstrated that Sema-4D
can potentiate the invasiveness of pancreatic cancer cells.
In the present study, we found that SAHA downregulated
Sema-4D expression in PaTu8988 cells, which may be one
the mechanism responsible for VM disruption. To our
knowledge, this is the first report showing SAHA affects
Sema-4D expression and cancer cell VM.
Integrin β5 is another potent angiogenic gene whose
expression in PaTu8988 cells was also suppressed by
SAHA. Integrins are a family of non-covalently associ-
ated het-erodimeric cell surface receptors composed of a
α and β subunit that mediate cell-ECM and cell-cell ad-
hesions [38]. It is reported that mice lack of integrin β3
and β5 showed less tumorigenesis [39]. We found that
PaTu8988 cells treated with SAHA showed inhibited ex-
pression of integrin β5, another mechanism to explain
SAHA’s anti-angiogenic potential.
Pancreatic cancers are among the most intrinsically re-
sistant tumors to almost all classes of cytotoxic drugs
[38]. The extremely high level of drug resistance was as-
sociated with dysregulation of multiple signaling path-
ways [39,40]. One key signaling pathway that is frequently
over-activated in pancreatic cancer is Akt/mTOR signal-
ing cascade [39,40], which is responsible for cancer cell
survival, proliferation, apoptosis-resistance, migration and
metastasis [39,40]. The fact that SAHA significantly
inhibited Akt and S6 activation in PaTu8988 cells might
explain its inhibitory efficiency against this cell line. As a
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hibitor, significantly inhibited PaTu8988 cell proliferation,
migration and survival (Data not shown).
Importantly, recent studies have indicated that Akt
signaling is also important for cancer cell vasculogenic
mimicry [30,31]. In PaTu8988 cells, both Akt inhibitor
perifosine [41] and SAHA inhibited Sema-4D expres-
sion. Thus SAHA-exerted inhibitory effect against VM
could also be associated Akt inhibition. More direct evi-
dence is, however, needed to further support this hy-
pothesis. In many cancer cells, over-expression or over-
activation of growth factor receptors (i.e. EGFR, PDGFR)
causes Akt hyper-activation [42]. Various inhibitors have
been developed to target cell surface receptors or Akt
(i.e. perifosine) for clinical use against cancers [42-45]. We
found that SAHA significantly down-regulated EGFR and
PDGFR expressions in PaTu8988 cells, which might be
responsible for Akt inhibition. Once again, more direct
evidence is still needed.
Conclusions
In summary, the above data demonstrated that SAHA
possesses its anti-pancreatic cancer ability by inducing
cell cycle arrest and cell apoptosis as well as suppressing
tumor in vitro cell migration and VM. Akt inhibition
might be associated with SAHA’s inhibitory efficiency.
Thus SAHA may be a potential anti-VM candidate for
anti-pancreatic cancer therapy.
Abbreviations
SAHA: Suberoylanilide hydroxamic acid; VM: Vasculogenic mimicry;
Sema-4D: Semaphorin-4D.
Competing interests
The authors have no conflict of interests. There were no financial
competing interests.
Authors’ contributions
XX, LZ, LY, YP, ZC, ZZ and QZ carried out the experiments. XX, LY, LZ, CC and
BY participated in the design of the study and performed the statistical
analysis. XX, LY, CC and BY conceived of the study, and participated in its
design and coordination and helped to draft the manuscript. All authors
read and approved the final manuscript.
Author details
1Department of General Surgery, the Third Hospital affiliated to Soochow
University, Changzhou City 213003, Jiangsu, China. 2Department of
Neurology, the First Affiliated Hospital of Soochow University, Suzhou, China.
3Cyrus Tang Hematology Center, Soochow University, Suzhou 215123,
Jiangsu, China. 4Jiangsu Key Laboratory of Translational Research and
Therapy for Neuro-Psycho-Diseases and Institute of Neuroscience, Soochow
University, Suzhou 215021, Jiangsu, China.
Received: 26 July 2013 Accepted: 16 May 2014
Published: 27 May 2014
References
1. Tinari N, De Tursi M, Grassadonia A, Zilli M, Stuppia L, Iacobelli S, Natoli C: An
epigenetic approach to pancreatic cancer treatment: the prospective role
of histone deacetylase inhibitors. Curr Cancer Drug Targets 2012, 12:439–452.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D,
Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S,Hachey M, Kirch R, Jemal A, Ward E: Cancer treatment and survivorship
statistics, 2012. CA Cancer J Clin 2012, 62:220–241.
3. Yeo CJ, Cameron JL: Improving results of pancreaticoduodenectomy for
pancreatic cancer. World J Surg 1999, 23:907–912.
4. Assifi MM, Hines OJ: Anti-angiogenic agents in pancreatic cancer: a
review. Anticancer Agents Med Chem 2011, 11:464–469.
5. Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W,
Sandvold ML: Gemcitabine chemoresistance in pancreatic cancer: molecular
mechanisms and potential solutions. Scand J Gastroenterol 2009, 44:782–786.
6. Weis SM, Cheresh DA: Tumor angiogenesis: molecular pathways and
therapeutic targets. Nat Med 2011, 17:1359–1370.
7. Potente M, Gerhardt H, Carmeliet P: Basic and therapeutic aspects of
angiogenesis. Cell 2011, 146:873–887.
8. Folberg R, Hendrix MJ, Maniotis AJ: Vasculogenic mimicry and tumor
angiogenesis. Am J Pathol 2000, 156:361–381.
9. Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S, Ni C, Wang X, Liu Y, Zhang L:
Role and mechanism of vasculogenic mimicry in gastrointestinal stromal
tumors. Hum Pathol 2008, 39:444–451.
10. Guzman G, Cotler SJ, Lin AY, Maniotis AJ, Folberg R: A pilot study of
vasculogenic mimicry immunohistochemical expression in
hepatocellular carcinoma. Arch Pathol Lab Med 2007, 131:1776–1781.
11. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV,
Hendrix MJ: Tumor cell vasculogenic mimicry: from controversy to
therapeutic promise. Am J Pathol 2012, 181:1115–1125.
12. Favier J, Plouin PF, Corvol P, Gasc JM: Angiogenesis and vascular
architecture in pheochromocytomas: distinctive traits in malignant
tumors. Am J Pathol 2002, 161:1235–1246.
13. Lin SZ, Wei WT, Chen H, Chen KJ, Tong HF, Wang ZH, Ni ZL, Liu HB, Guo HC,
Liu DL: Antitumor activity of emodin against pancreatic cancer depends on
its dual role: promotion of apoptosis and suppression of angiogenesis. PLoS
One 2012, 7:e42146.
14. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P,
Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors: the
hydroxamic acid derivative LBH589. Clin Cancer Res 2006, 12:634–642.
15. Kelly WK, O’Connor OA, Marks PA: Histone deacetylase inhibitors: from
target to clinical trials. Expert Opin Investig Drugs 2002, 11:1695–1713.
16. Marks PA: Discovery and development of SAHA as an anticancer agent.
Oncogene 2007, 26:1351–1356.
17. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N,
Chumakov A, Imai Y, Koeffler HP: Histone deacetylase inhibitor, suberoylanilide
hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human
pancreatic cancer cells. Int J Cancer 2007, 121:656–665.
18. Ma X, Yang Y, Wang Y, An G, Lv G: Small interfering RNA-directed
knockdown of S100A4 decreases proliferation and invasiveness of
osteosarcoma cells. Cancer Lett 2010, 299:171–181.
19. Zhou Q, Kiosses WB, Liu J, Schimmel P: Tumor endothelial cell tube
formation model for determining anti-angiogenic activity of a tRNA
synthetase cytokine. Methods 2008, 44:190–195.
20. Zhou Q, Kapoor M, Guo M, Belani R, Xu X, Kiosses WB, Hanan M, Park C,
Armour E, Do MH, Nangle LA, Schimmel P, Yang XL: Orthogonal use of a
human tRNA synthetase active site to achieve multifunctionality.
Nat Struct Mol Biol 2010, 17:57–61.
21. Cao C, Huang X, Han Y, Wan Y, Birnbaumer L, Feng GS, Marshall J, Jiang M,
Chu WM: Galpha(i1) and Galpha(i3) are required for epidermal growth
factor-mediated activation of the Akt-mTORC1 pathway. Sci Signal 2009,
2:ra17.
22. Cao C, Sun Y, Healey S, Bi Z, Hu G, Wan S, Kouttab N, Chu W, Wan Y:
EGFR-mediated expression of aquaporin-3 is involved in human skin
fibroblast migration. Biochem J 2006, 400:225–234.
23. Roy SK, Srivastava RK, Shankar S: Inhibition of PI3K/AKT and MAPK/ERK
pathways causes activation of FOXO transcription factor, leading to cell
cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010, 5:10.
24. Parsons CM, Muilenburg D, Bowles TL, Virudachalam S, Bold RJ: The role of
Akt activation in the response to chemotherapy in pancreatic cancer.
Anticancer Res 2010, 30:3279–3289.
25. Furukawa T: Molecular targeting therapy for pancreatic cancer: current
knowledge and perspectives from bench to bedside. J Gastroenterol 2008,
43:905–911.
26. Falasca M, Selvaggi F, Buus R, Sulpizio S, Edling CE: Targeting phosphoinositide
3-kinase pathways in pancreatic cancer–from molecular signalling to clinical
trials. Anticancer Agents Med Chem 2011, 11:455–463.
Xu et al. BMC Cancer 2014, 14:373 Page 13 of 13
http://www.biomedcentral.com/1471-2407/14/37327. Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A: Synergic antiproliferative
and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic
cancer cells. Biochem Pharmacol 2008, 75:1035–1044.
28. He L, Wu Y, Lin L, Wang J, Chen Y, Yi Z, Liu M, Pang X: Hispidulin, a small
flavonoid molecule, suppresses the angiogenesis and growth of human
pancreatic cancer by targeting vascular endothelial growth factor receptor
2-mediated PI3K/Akt/mTOR signaling pathway. Cancer Sci 2011, 102:219–225.
29. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC,
Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C,
Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M: Integrated
preclinical and clinical development of mTOR inhibitors in pancreatic
cancer. Br J Cancer 2010, 103:649–655.
30. Hess AR, Seftor EA, Seftor RE, Hendrix MJ: Phosphoinositide 3-kinase regulates
membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity
during melanoma cell vasculogenic mimicry. Cancer Res 2003, 63:4757–4762.
31. Mei J, Gao Y, Zhang L, Cai X, Qian Z, Huang H, Huang W: VEGF-siRNA silencing
induces apoptosis, inhibits proliferation and suppresses vasculogenic
mimicry in osteosarcoma in vitro. Exp Oncol 2008, 30:29–34.
32. Lu JH, Shi ZF, Xu H: The mitochondrial cyclophilin D/p53 complexation
mediates doxorubicin-induced non-apoptotic death of A549 lung cancer
cells. Mol Cell Biochem 2014, 389:17–24.
33. Glantschnig H, Rodan GA, Reszka AA: Mapping of MST1 kinase sites of
phosphorylation. Activation and autophosphorylation. J Biol Chem 2002,
277:42987–42996.
34. Chen B, Xu M, Zhang H, Wang JX, Zheng P, Gong L, Wu GJ, Dai T:
Cisplatin-induced non-apoptotic death of pancreatic cancer cells
requires mitochondrial cyclophilin-D-p53 signaling. Biochem Biophys Res
Commun 2013, 437:526–531.
35. Chen MB, Wu XY, Tao GQ, Liu CY, Chen J, Wang LQ, Lu PH: Perifosine sensitizes
curcumin-induced anti-colorectal cancer effects by targeting multiple
signaling pathways both in vivo and in vitro. Int J Cancer 2012, 131:2487–2498.
36. Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y, Su L: MicroRNA-141 regulates
Smad interacting protein 1 (SIP1) and inhibits migration and invasion of
colorectal cancer cells. Dig Dis Sci 2010, 55:2365–2372.
37. Fabre M, Garcia De Herreros A: Phorbol ester-induced scattering of HT-29
human intestinal cancer cells is associated with down-modulation of
E-cadherin. J Cell Sci 1993, 106(Pt 2):513–521.
38. Spalletta G, Cravello L, Piras F, Iorio M, Sancesario G, Marchi A, Caltagirone C,
Cacciari C: Rapid-onset apathy may be the only clinical manifestation
after dorsal striatum hemorrhagic lesion: a case report. Alzheimer Dis
Assoc Disord 2013, 27:192–194.
39. Costello E, Neoptolemos JP: Pancreatic cancer in 2010: new insights
for early intervention and detection. Nat Rev Gastroenterol Hepatol
2011, 8:71–73.
40. Kim J, Kim YC, Fang C, Russell RC, Kim JH, Fan W, Liu R, Zhong Q, Guan KL:
Differential regulation of distinct Vps34 complexes by AMPK in nutrient
stress and autophagy. Cell 2013, 152:290–303.
41. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi
NC, Chauhan D, Richardson PG, Anderson KC: Perifosine, an oral bioactive novel
alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in
human multiple myeloma cells. Blood 2006, 107:4053–4062.
42. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in
human cancer. Nat Rev Cancer 2002, 2:489–501.
43. Ravindran J, Prasad S, Aggarwal BB: Curcumin and cancer cells: how many
ways can curry kill tumor cells selectively? AAPS J 2009, 11:495–510.
44. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E,
Dicato M, Diederich M: Chemopreventive and therapeutic effects of
curcumin. Cancer Lett 2005, 223:181–190.
45. Liu J, Mao W, Ding B, Liang CS: ERKs/p53 signal transduction pathway
is involved in doxorubicin-induced apoptosis in H9c2 cells and
cardiomyocytes. Am J Physiol Heart Circ Physiol 2008, 295:H1956–1965.
doi:10.1186/1471-2407-14-373
Cite this article as: Xu et al.: Suberoylanilide hydroxamic acid, an
inhibitor of histone deacetylase, suppresses vasculogenic mimicry and
proliferation of highly aggressive pancreatic cancer PaTu8988 cells. BMC
Cancer 2014 14:373.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
